Nevertheless, Dinaciclib, which is a selective CDK inhibitor targeting CDK1, CDK2, CDK5, and CDK9, appears to be insufficient in conclusively demonstrating the role of CDK2 in tumor immunogenicity (3, 38) and a role for the specific inhibition of CDKs in inducing ICD has not been described. This evidence concerns the gene CDK2 and neoplasm.